Compare OSBC & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | AAPG |
|---|---|---|
| Founded | 1981 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2014 | 2024 |
| Metric | OSBC | AAPG |
|---|---|---|
| Price | $24.32 | $14.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $28.00 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 593.1K | 4.6K |
| Earning Date | 10-21-2026 | 08-19-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.70 | $18.59 |
| Revenue Next Year | $1.71 | $120.05 |
| P/E Ratio | $24.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.61 | $14.46 |
| 52 Week High | $26.06 | $34.50 |
| Indicator | OSBC | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 39.79 |
| Support Level | $24.01 | N/A |
| Resistance Level | $25.77 | $16.41 |
| Average True Range (ATR) | 0.56 | 0.48 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 34.81 | 3.91 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.